Posted by Michael Wonder on 26 Oct 2024
Lenz Therapeutics announces FDA acceptance of new drug application for LNZ100 for the treatment of presbyopia
21 October 2024 - FDA sets PDUFA target date of 8 August 2025.
Lenz Therapeutics today announced that the US FDA has accepted the Company’s new drug application for LNZ100 for the treatment of presbyopia.
Read Lenz Therapeutics press release
Posted by:
Michael Wonder